KUALA LUMPUR - The Health Ministry (MOH) has approved CanSino's single-dose Convidecia vaccine to be used as a heterologous booster with all Covid-19 primary vaccines in Malaysia.
Solution Group Bhd, the Asean manufacturing partner of CanSino Biologics Inc in a statement today said the vaccine was approved for adults aged 18 years and older, regardless of the type of vaccine they received during their earlier Covid-19 vaccination.
The statement also stated Convidecia will be given as a booster dose after at least three months of recipients receiving the second dose of their primary vaccination
"It is also the first and only Covid-19 vaccine from China to be included in the heterologous vaccination programme in Malaysia that can be administered as a mix-and-match with both Pfizer-BioNTech and AstraZeneca COVID-19 vaccines," the statement said.
In the same statement, SGB's deputy group managing director Datuk Dr Mohd Nazlee Kamal said recent studies in China showed the usage of Convidecia as a heterologous booster, via either intramuscular injection or using the inhaled version, generated greater neutralizing antibody responses.
In addition, he said the vaccine's safety profile in real-life usage was also backed by the Mexican health authorities' Events Supposedly Attributable to Vaccination or Immunisation (ESAVI) Report released recently. - Bernama
Solution Group Bhd, the Asean manufacturing partner of CanSino Biologics Inc in a statement today said the vaccine was approved for adults aged 18 years and older, regardless of the type of vaccine they received during their earlier Covid-19 vaccination.
The statement also stated Convidecia will be given as a booster dose after at least three months of recipients receiving the second dose of their primary vaccination
"It is also the first and only Covid-19 vaccine from China to be included in the heterologous vaccination programme in Malaysia that can be administered as a mix-and-match with both Pfizer-BioNTech and AstraZeneca COVID-19 vaccines," the statement said.
In the same statement, SGB's deputy group managing director Datuk Dr Mohd Nazlee Kamal said recent studies in China showed the usage of Convidecia as a heterologous booster, via either intramuscular injection or using the inhaled version, generated greater neutralizing antibody responses.
In addition, he said the vaccine's safety profile in real-life usage was also backed by the Mexican health authorities' Events Supposedly Attributable to Vaccination or Immunisation (ESAVI) Report released recently. - Bernama